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a b s t r a c t
PB1-F2 is a small inﬂuenza A virus (IAV) protein encoded by an alternative reading frame of the PB1 gene.
During IAV infection, antibodies to PB1-F2 proteins are induced. To determine their function and
contribution to virus infection, three distinct approaches were employed: passive transfer of anti-PB1-F2
MAbs and polyclonal antibodies, active immunization with PB1-F2 peptides and DNA vaccination with
plasmids expressing various parts of PB1-F2. Mostly N-terminal speciﬁc antibodies were detected in
polyclonal sera raised to complete PB1-F2. Passive and active immunization revealed that antibodies
recognizing the N-terminal part of the PB1-F2 molecule have no remarkable effect on the course of IAV
infection. Interestingly antibodies against the C-terminal region of PB1-F2, obtained by immunization
with KLH-PB1-F2 C-terminal peptide or DNA immunization with pC-ter.PB1-F2 plasmid, partially
protected mice against virus infection. To our knowledge, this is the ﬁrst report demonstrating the
biological relevance of humoral immunity against PB1-F2 protein in vivo.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Inﬂuenza continues to be a major public health problem. The
World Health Organization (WHO) estimates that in a typical year,
10–20% of the world's population is infected with inﬂuenza,
resulting in 3–5 million severe illnesses and up to half a million
deaths. During pandemics, the losses are even greater. Pandemic
global outbreaks have caused severe illness with high mortality
rates; the 1918 Spanish outbreak in particular killed at least
20 million people worldwide. Currently, the most efﬁcient strategy
for control of inﬂuenza is yearly vaccination (Morens et al., 2010;
Stohr, 2003; Taubenberger and Morens, 2006).
The ﬂu is caused by the inﬂuenza virus which is a segmented,
enveloped, and negative strand RNA virus. The genome of inﬂu-
enza virus consists of eight separate RNA segments that code for
viral proteins: two envelope glycoproteins-hemagglutinin (HA)
and neuraminidase (NA), matrix protein (M1), an ion channel
protein (M2), nucleoprotein (NP), three proteins of polymerase
complex (PB1, PB2 and PA), non-structural proteins NS1 and
nuclear export protein (NEP/NS2), until recently considered to be
non-structural protein (Muramoto et al., 2013; Shi et al., 2012).
While searching for alternative reading frame peptides encoded by
inﬂuenza A viruses (IAV) that are recognized by CD8þT cells, a
PB1-F2 protein encoded by the (þ1) ORF in PB1 gene was
discovered (Chen et al., 2001). PB1-F2 is also a nonstructural
protein. A third PB1-related protein translated from PB1, N40,
has recently been identiﬁed. In addition to its mode of translation,
PB1-F2 has several unique features. These include its absence from
some IAV isolates (Zell et al., 2007), variable expression in the
individual infected cells, rapid degradation, mitochondrial locali-
zation, formation of a nonselective ion channel (Henkel et al.,
2010; Chen et al., 2001; Yamada et al., 2004), and apoptotic or pro-
apoptotic properties. Further studies using mouse models support
a role for PB1-F2 in pathogenicity and lethality (Alymova et al.,
2011; de Wit et al., 2008; McAuley et al., 2010b) probably by
disrupting a function of alveolar macrophages (Coleman, 2007).
IAVs knocked out for the expression of PB1-F2 were not attenuated
in the replication in tissue culture, but their pathogenicity and
lethality for mice was considerably reduced. Also, PB1-F2-
knockout viruses were cleared from lungs more rapidly and
induced earlier immune response to the infection (Zamarin
et al., 2006) implying that PB1-F2 played a role in the suppression
of immune response responsible for viral clearance. PB1-F2
enhances inﬂammation during the primary viral infection of mice
and increases both the frequency and severity of secondary
bacterial pneumonia (McAuley et al., 2007).
During IAV infections, Abs are generated to both structural
(HA, NA, NP, NS2, M1, M2,) and non-structural protein (NS1). Only
Abs to HA can efﬁciently neutralize virus infectivity. Antibodies to
PB1-F2 protein are induced in response to inﬂuenza A virus infection
(Krejnusova et al., 2009). We have shown that PB1-F2-speciﬁc Abs
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
0042-6822/$ - see front matter & 2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.virol.2013.08.022
n Corresponding author.
E-mail address: virugrus@savba.sk (G. Russ).
1 Authors contributed equally.
Virology 447 (2013) 1–8
could be detected via immunoprecipitation or immunoﬂuorescence
assays both in immune mouse and human convalescent sera. It has
been reported that humans generate anti-PB1-F2 antibodies, as
measured using a phage library expressing PB1-F2 sequences
(Khurana et al., 2009). It is not known whether these antibodies
can modulate the functional outcomes of PB1-F2 expression and
course of disease. In the present study, we have used a number of
assays for analysis of anti-PB1-F2 antibody responses, focusing on
their effect on virus infection. We ﬁnd that PB1-F2 speciﬁc antibodies
directed against the C-terminal part of the molecule reasonably
protect mice against IAV infection. On the other hand PB1-F2 speciﬁc
antibodies which are directed predominantly to the N-terminal part
of the molecule do not remarkably affect course of infection. Based
on this analysis and the data presented in this study, it is clear that
the biological relevance of anti-PB1-F2 speciﬁc antibodies in IAV
infections is complex.
Results and discussion
“In silico” analysis predicts that PB1-F2 speciﬁc antibodies are
most likely induced to the N-terminal part of PB1-F2 molecule.
Initially we applied “in silico” analysis for prediction of epitopes
(B cell epitopes) recognized by PB1-F2 speciﬁc antibodies in immune
sera. The complex prediction of beta-turns (Fig. 1A.1), accessibi-
lity (Fig. 1A.2), ﬂexibility (Fig. 1A.3), hydrophilicity (Fig. 1A.4),anti-
genic propensity (Fig. 1A.6), was performed (December 2012http://
tools.immuneepitope.org/tools/bcell/iedb_input). Although widely
employed immunogenicity prediction algorithm (Kolaskar and
Tongaonkar, 1990) (Fig. 1A.5) has predicted antibody binding sites
even in the C-terminus, novel BepiPred method using a combination
of a hidden Markov model and a propensity scale method deter-
mined a major antibody binding site in the N-terminus (Fig. 1A). Five
out of six analyses predict antibody binding sites in N-terminal part
of the PB1-F2, one in both N-terminal a C-terminal parts of the
molecule and one mainly in the C-terminal part.
ELISA with peptides corresponding to various regions of PB1-F2
and immunoﬂuorescence conﬁrmed that N-terminal part of mole-
cule is the major target for speciﬁc antibodies.
To validate the outcome of “in silico” analysis, PB1-F2 speciﬁc
serum obtained by immunization of mice with puriﬁed PB1-F2-
MBP protein was performed. As shown in Fig. 1B, typical serum
contained antibodies recognizing in ELISA predominantly
N-terminal peptide (3–13aa) and less efﬁciently also C-terminal
peptide (65–87aa). According to “in silico” analysis, speciﬁc anti-
body binding sites should also be localized in region 14–41.
Regrettably, no peptide(s) corresponding to this region was avail-
able. Accordingly, results of peptide ELISA correspond properly
with “in silico“analysis. Interestingly, PB1-F2 speciﬁc MAb AG55
(Fig. 1C) bind only to N-terminal peptide (3–13). We are aware that
direct binding of short peptides to the surface of plate partially or
completely abolishes their conformation and mobility. Therefore
PB1-F2 speciﬁc antibodies (recognizing conformational epitopes)
could not be detected in such ELISA setting. To exclude direct
binding, N-terminally biotinylated peptides derived from PB1-F2
ORF (7–16aa or 62–71aa) were attached to streptavidin pre-coated
plate. Streptavidin pre-coated or direct coating of N terminally
biotinylated peptides derived from PB1-F2 ORF (7–16aa or
62–71aa) was compared in its ability to interact with IMS anti
PB1-F2-MBP (supplementary Fig. 1). Streptavidin pre-coating of
wells and capture of PB1-F2 ORF derived peptides (7–16aa,
62–71aa) via biotin even worsened reactivity of all the screened
anti PB1-F2-MBP sera. Employing of irrelevant IMS raised after
MHV68 infection and irrelevant peptide derived from HA2 ORF
(170–178aa) conﬁrmed high speciﬁcity and relevance of used ELISA
assay. In the experiments that followed we replaced peptide ELISA
with indirect immunoﬂuorescence of MDCK cells transiently trans-
fected with pPB1-F2, pNter.PB1-F2, pCter.PB1-F2 and pPB1-F2 Stop
3aa, respectively. Similarly as in peptide ELISA PB1-F2 speciﬁc
antibodies were detected in the immune sera raised against PB1-
F2-MBP. Conformation is well preserved under these conditions. In
immunoﬂuorescence experiments the positive staining was
detected only in transfected MDCK cells expressing either full
length (pPB1-F2) or N-terminal part of PB1-F2 (pNter.PB1-F2)
(Fig. 1D upper row). Interestingly, the staining pattern of MDCK
cells expressing full length of PB1-F2 was apparently different
from staining pattern corresponding to N-terminal part of PB1-F2.
We assume that in MDCK cells full length PB1-F2 is localized in
mitochondria, however N-terminal part PB1-F2 missing C-terminal
mitochondrial localization signal is spread through cytosol and
nucleus. Similarly nuclear localization of the PB1-F2 is typical for
avian strain derived PB1-F2 (Chen et al., 2010; Kosik et al., 2013).
We were unable to detect speciﬁc staining of MDCK cells expressing
C-terminal part of PB1-F2. Although weak a clear signal was
detected in ELISA for C-terminal peptide no staining of cells was
seen in cells transfected by pCter.PB1-F2 following incubation with
PB1-F2 speciﬁc serum obtained by immunization of mice with
puriﬁed full length PB1-F2-MBP. We believe that this discrepancy
can be explained by the higher sensitivity of ELISA as compared
with indirect immunoﬂuorescence of transfected cells. To conﬁrm
expression ability and transfection efﬁciency of the pPB1-F2, pNter.
PB1-F2, pCter.PB1-F2 samples from the same transfection experi-
ment were stained with PB1-F2 N terminally speciﬁc MAb (AG55)
or PB1-F2-C terminally speciﬁc IMS anti PB1-F2 C73–87 –KLH
respectively. As expected AG55 positive staining was only observed
in the case of full length or N terminal part of the PB1-F2 (Fig. 1D
middle row), while positive staining of transfected cells with IMS
anti PB1-F2-C73–87 –KLH was only observed in the case of full length
or C terminal part of the PB1-F2 (Fig. 1D below row). Neither IMSs
nor MAb stained cells transfected by pPB1-F2 Stop3aa. To ensure no
detectable expression of the PB1-F2 protein after transfection by
pPB1-F2 Stop3aa western blot analysis was performed. It was not
possible to detect PB1-F2 in cells transfected with pPB1-F2 Stop3aa
or cells transfected with insert less plasmid pTriEx4 (Merck) neither
with MAb AG55 nor IMS anti PB1-F2-MBP. Strong expression of the
PB1-F2 protein was detected both MAb AG55 or IMS anti PB1-F2-
MBP in the case of transfection with pPB1-F2 (supplementary
Fig. 2). Based on the above presented results we suggest that PB1-
F2 speciﬁc antibodies bind predominantly to the N-terminal part of
the molecule.
Passive immunization with N-terminally speciﬁc MAbs has no
remarkable effect on the course of infection.
To examine the effect of PB1-F2 speciﬁc antibody on virus
infection, the mixture of two MAbs AG55 and LB66 was ﬁrst
passively transferred to a group of mice by intravenous rout and
the mice were subsequently (within 2 h) challenged by PR8
(1LD50). For positive control, the group of mice were passively
immunized with HA speciﬁc MAb H17L2, highly efﬁcient in virus
neutralization. In negative control the mice received HHV2 speciﬁc
MAb 499. All MAbs used for passive immunization were of the
same isotype. Survival rates and body weight changes were
monitored daily. Virus in the lungs was determined by RCA on
day 2, 6 and 10 days post infection. Two days post infection the
similar titer of virus was detected in lungs of mice passively
immunized with the mixture of N terminally PB1-F2 speciﬁc MAbs
as in mice immunized with a negative control MAb or PBS
respectively. As expected in the lungs of mice immunized H17L2
MAb there was almost no virus detected 2 days post infection. Six
days post infection the virus in lungs was clearly detected only in
mice immunized with negative control MAb and PBS. Ten days
post infection, no virus was detected in the lungs of any groups of
mice (Fig. 1A). Although weight loss was most remarkable in the
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Fig. 1. In silico and in vitro analysis of immunogenic regions of PB1-F2 was performed. A complex web based tool for linear B cell epitopes prediction (http://tools.
immuneepitope.org/tools/bcell) was employed to identify potential immunogenic sequential epitopes of PB1-F2. (A) Multiple parameters affecting immunogenicity were
studied, including (A1) Beta-turn, (A2) surface accessibility, (A3) ﬂexibility, (A4) hydrophilicity, two most recently used algorithms (A5) Kolaskar and Tongaonkar and (A6)
Bepipred Linear Epitope Prediction of antigenicity prediction was also employed. (B) Eight PB1-F2 derived peptides were used to identify their interaction with antibobies
presented in the polyclonal sera. Microtiter plates were coated by eight different PB1-F2 derived peptides (100 ng/well). Two hundred-fold diluted of IMSs raised after
immunization with full length PB1-F2-MBP fusion protein were added to wells. Plate was washed and secondary HRP anti mouse and OPD substrate was subsequently
incubated in the plate. Developed signal was measured by ELISA reader. All the samples were measured in triplicate. (C) The same procedure was performed with MAb AG55.
(D) Abs recognizing conformational epitopes were evaluated in the serum raised to full length PB1-F2. Immunoﬂuorescence was performed 24 h post transfection with
plasmids expressing full length, N-terminal half, C-terminal half and Stop3aa mutant protein PB1-F2. Three slides were placed to each well of the six well plate and cells were
added. At 60–70% conﬂuence transfection mixtures was added and 24 later samples were ﬁxed and permeabilized. Samples were individually incubated with 250-fold
diluted IMS anti PB1-F2-MBP (upper row) and stained with 100-fold diluted goat anti mouse FITC conjugated secondary antibody (DAKO) or with undiluted hybridoma
supernatant containing N terminally speciﬁc MAb AG55 (middle row) and stained with 100-fold diluted goat anti mouse Texas Red conjugated secondary antibody (Sigma-
Aldrich) or with 50-fold diluted IMS anti C73–87-KLH (lower row) and stained with 100-fold diluted goat anti mouse Texas Red secondary antibody (Sigma-Aldrich). After ﬁnal
washing samples and mounting with DAPI containing mounting medium (Santacruz Biotechnologies) samples were analyzed by confocal microscope Zeiss LSM 510 Meta.
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negative control groups (Fig. 2B), only 50% of mice succumbed to
infection in MAb 499 anti HHV2 treated group of mice while in
both AG55þLB66 as well as PBS treated groups of mice more than
60% of the mice died (Fig. 2C). Despite some nonspeciﬁc effect was
observed for negative MAb 499 treated group, comparison of the
AG55þLB66 and PBS treated group clearly shown neglible effect of
N terminaly speciﬁc MAbs (Fig. 2A–C).
Passive immunization with polyclonal PB1-F2 speciﬁc anti-
bodies has no signiﬁcant effect on the course of infection.
Our next point of interested was whether or not passive
immunization with polyclonal PB1-F2 speciﬁc antibodies has a
similar effect on IAV infection as N-terminus MAbs, or whether
it is general property of anti-PB1-F2 antibody response. In these
experiments mice were immunized with full length protein
PB1-F2-MBP. Sera with anti PB1-F2 antibody titer higher than
1600 (determined by ELISA, Table 1) were pooled and used for
puriﬁcation for passive immunization experiments. As a positive
control, IgG puriﬁed from serum of PR8 infected mice was used.
In negative control the group of mice was passively immunized
with IgG puriﬁed from sera of mice immunized with protein
MBP or PBS. Two hr p.i. mice were infected with PR8 (1LD50).
The survival rate and body weight changes were monitored
daily. In comparison to the negative control groups, lung virus
titer twice as low was detected in IgG for anti PB1-F2-MBP and
comparable virus titer was detected in PBS control group
(Fig. 2D) group 2DPI. Despite decreased viral lung load and
equal weight change having been observed (Fig. 2E), 80% of mice
immunized with IgG anti PB1-F2-MBP succumbed and 70% of
mice in the negative control group immunized with IgG anti
MBP succumbed as well (Fig. 2F). In PBS negative control group
even 90% of the mice have died. Similarly to passive immuniza-
tion with N terminally PB1-F2 speciﬁc MAbs such immunization
with polyclonal PB1-F2 speciﬁc antibodies does not signiﬁcantly
affect the survival rate of mice following IAV infection. As
described earlier, polyclonal speciﬁc antibodies present in
serum obtained by immunization with PB1-F2-MBP bind pre-
dominantly to the N-terminal part of the molecule. Neverthe-
less, such serum also contains antibodies directed against
C-terminal part of PB1-F2 at a low level. As C-terminal speciﬁc
MAbs were not available, we decided to study the effect of active
immunization using PB1-F2 peptides conjugated with KLH and
Fig. 2. Passive transfer of PB1-F2 speciﬁc MAbs and PAbs was used to determine the role of humoral immune response during the course of IAV infection. (A) In days post
infection as indicated, two mice per group were sacriﬁced, lungs were homogenated in PBS and centrifuged in 4000 RPM for 10 min. Supernatant was used for RCA as
described in materials and methods section. Duplicate samples were analyzed. Virus titer was determined as reciprocal of highest dilution producing positive staining of
cells. (B) For severity of infection measurement of the body weight changes for individual mouse and (C) rate of survival was recorded and plotted. The same procedure was
applied in the case of the passive transfer of IgG fraction of polyclonal serum (D, E, F). Error bars indicate SD values. An asterisk indicates a signiﬁcant (Po0,05) difference by
two-tailed Student t-test compared to results determined for negative control group (PBS).
Table 1
PB1-F2 speciﬁc antibody titer of individual IMS raised after PB1-
F2-MBP immunization. 100 ng of synthetic full length PB1-F2
protein was coated on 96 well microtiter plate and absorbed
overnight. Individual IMS/NMS were tested on presence and titer
of PB1-F2 speciﬁc antibodies. Sera were pooled and used for
puriﬁcation for passive immunization experiments. Sera chosen
for IgG puriﬁcation and passive transfer are indicated with ¤.
IMS titer IMS anti PB1-F2-MBP
1¤ 25,600
2¤ 3200
3¤ 12,800
4¤ 12,800
5¤ 6400
6 800
7¤ 6400
8¤ 51,200
9¤ 6400
10¤ 3200
11¤ 51,200
12 800
13¤ 12,800
14¤ 6400
15 1600
16¤ 6400
17 1600
18 800
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DNA immunization with plasmids allowing for expression of
different parts of PB1-F2 molecule.
Active immunization revealed the protective potential of
C-terminal part of the PB1-F2.
We ﬁrst immunized a group of mice with two doses of PB1-F2
peptides (N3–13, M42–53 or C71–83) conjugated to KLH. The positive
control group was immunized with puriﬁed PR8 virus IAV and the
negative control group with KLH protein. Before infection, speciﬁc
antibody induction was measured by ELISA; sera obtained by
immunization with one peptide bind very well to this peptide
but did not cross react with remaining peptides (supplementary
Fig. 3A ). Mice were infected intranasally with PR8/IAV (1 LD50).
The survival rate and body weight changes were monitored daily.
As RCA method was capable to detect virus level till 6DPI we had
switched to much more sensitive detection of vRNA by RT-PCR.
Viral RNA load on 2, 6, 10DPI, body weight changes and survival
rate were monitored 14DPI. In comparison to negative control
group (KLH) 2DPI, lung vRNA load was somewhat higher in all
experimental groups (Fig. 3A) (N3–13 orM42–53 or C71–83). In the
context of the above it was surprising that C71–83 peptide
immunized group exhibit decreased weight (Fig. 3B) but increased
% of survival (Fig. 3C) where 90% of mice survived.
In further experiments we employed DNA vaccination. DNA
vaccination mimics natural infection with its complex antigen
processing as well as immune response. Mice were i.m. immu-
nized with three doses of 50 mg of pPB1-F2 (1–87), pNter (1–50aa)
PB1-F2, pCter (51–87aa). PB1-F2, pHA, pPB1-F2 Stop 3aa and PBS
in two week intervals. Ten days post ﬁnal immunization, blood
was collected and serum assayed and the presence of immunogen-
speciﬁc Abs was conﬁrmed (supplementary Fig. 3B). Stop3aa
mutation construct was used as negative control. DNA vaccination
with plasmid expressing full length PB1-F2 resulted in a decrease
in the virus RNA level in comparison to PBS treated group (Fig. 3D).
Immunization with remaining plasmids expressing N-terminal,
C-terminal has a similar outcome as pPB1-F2 Stop 3aa DNA
vaccination. Despite higher level of viral NS RNA was detected in
the pC ter. PB1-F2 vaccinated group of mice on 2DPI and 6DPI in
comparison to pPB1-F2 or pN ter. PB1-F2, this group had exhibited
the lowest weight decrease and the highest survival. The effect of
stop mutant plasmid can be attributed to CpG adjuvant effect
Fig. 3. Effects of active immunization with peptide-KLH and DNAv representing distinct region of PB1-F2 was tested to determine immunological importance of
substructural domains of the PB1-F2 throughout the course of IAV infection. In days post infection as indicated, two mice per group were sacriﬁced, lungs were homogenated
in PBS and centrifuged in 4000 RPM for 10 min. Supernatant of the mice from the same group were pooled and used for whole RNA isolation with RNA isolation kit (Ecoli,
Slovakia). RNA was reverse transcribed with random hexamer primer and RT-PCR was employed to measure relative levels of inﬂuenza NS gene RNA several days post
infection. Beta-actin was used as endogenous control in each sample (A, D). Severity of infection was monitored daily. Individual mouse was weighted and body weight
change was plotted (B, E). Survival rate for all the experimental group was monitored for two weeks (C, F) and plotted. Error bars indicates SD values. An asterisk indicates a
signiﬁcant (Po0,05) difference by two-tailed Student t-test compared to results determined for negative control group (KLH or PBS).
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(Bode et al., 2011; Smahel et al., 2011). As follows from body
weight change and rate of survival, DNA immunization with
plasmid expressing C-terminus (51–87aa) induced excellent
protection with 100% of survival and minimal weight loss in the
indicated sublethal dose of infection 1LD50 (Fig. 3E, F). The DNA
vaccination against IAV elicits humoral as well as cellular
immune responses with protective potential (Charo et al.,
2004; Choi et al., 2009; Ilyinskii et al., 2008; Shen and Niu,
2012). PB1-F2 speciﬁc CTL probably play minor role in compar-
ison to PA or NP speciﬁc CTL response in mouse model
respectively (La Gruta et al., 2008). Nevertheless in DNA
vaccination with pCter (51–87aa) the contribution of CTL
response may not be excluded as pCter expresses experimen-
tally proved immunodominant PB1-F2 (62–70aa) MHCI binding
peptide (Chen et al., 2001; La Gruta et al., 2008). It follows
from active immunization experiments that antibodies against
C-terminal part of the PB1-F2 express reasonable protection
against IAV infection. As efﬁcient uptake of the C-terminal
derived peptide of the PB1-F2 was shown on macrophage cell
line J774 and C-terminus is considered to be responsible for
the immunopathology of IAV infection (McAuley et al., 2007;
McAuley et al., 2010a) antibodies speciﬁc to the C-terminal
region could inhibit these functions, especially in the later
phases of infection due to the cytopathic release of PB1-F2
from infected epithelial cells. Such released PB1-F2 molecules
can quickly enter other cells and induce their death due to the
presence of C-terminal part. Antibodies against the C-terminal
part of PB1-F2 could bind to released PB1-F2 molecules and
prevent their entry to other cells.
Conclusion
During IAV infection antibodies against the C-terminal part
of PB1-F2 are induced together with antibodies recognizing
N-terminal part of PB1-F2. Antibodies recognizing N terminal part
of the PB1-F2 have no signiﬁcant effect whereas antibodies against
C terminal part of the PB1-F2 partially protect mice against
infection. We assume that if both types of antibodies are present
the protective effect of antibodies against the C-terminal part of
PB1-F2 is lost. One possible explanation is that antibodies against
N-terminal PB1-F2 dominate over antibodies C-terminal part of
PB1-F2 during immune response. The biological relevance of anti-
PB1-F2 speciﬁc antibodies in IAV infections seems to be very
complex.
Materials and methods
Virus, cell line and mice: A/PR/8/34 (H1N1) (Kindly provided by
Dr. Yewdell, NIH, USA), MDCK and female six week old BALB/c
were used in this study. In all experiments presented in this paper,
animals were treated according to the European Union standards
and the fundamental ethical principles including animal welfare
requirements were respected.
Antibodies and antigen preparation:
MAb AG55speciﬁc to the N-terminal region of the PB1-F2
preparation has been previously described (Krejnusova et al.,
2009). N-terminal speciﬁc MAb LB66 was prepared by standard
hybridoma technique after immunization of the mice with peptide
N3–13 (CQEQDTPWILST) conjugated to KLH. KLH-C73–87 (KTRVL
KRWRLSFKHEC) peptide of the PB1-F2 was used for preparation of
the mouse PAbs. Additional peptides M42–53 (CQKTMNQVVMPK)
and C71–83 (CFLKTRVLKRWRLF) were conjugated to KLH via
m-maleimidobenzoyl-N-hydoxysuccinimide ester (Thermo Scien-
tiﬁc) by the protocol recommended by supplier in order of PAbs
induction. Biotin-TPWILSTGHIWEREC7–16, Biotin-WLSLRNPILVF-
LC62–71 and irrelevant peptide HA2 derived RFQIKGVEL170–178 used
in ELISA were produced by, Metabion, Germany. Synthetic full
length protein PB1-F2 derived from PR8 virus was used for PB1-F2
speciﬁc antibody level determination (Roder et al., 2008). The
remaining peptides corresponding to different regions of the PB1-
F2 molecule were kindly provided by Dr. Yewdell (NIH, USA). All
the peptides and plasmid coded sequences used in described
experiments are summarized in Fig. 4. MBP and fusion protein
PB1-F2-MBP were prepared using the pMAL-c2X.MBP Protein
Fusion and Puriﬁcation System (New England Biolabs). Monoclo-
nal and polyclonal antibodies were puriﬁed by standard procedure
on protein A sepharose collumn.
For PAbs preparation, groups of 18 BALB/c mice were i.p.
immunized with three doses of approximately 15 mg PB1-F2-MBP
or about 15 mg MBP with complete or incomplete Freund's
adjuvant per mouse in three-week intervals. Sera were collected
two weeks after last dose. Monoclonal and polyclonal antibodies
were puriﬁed by standard procedure on protein A sepharose
column.
MAb 499 speciﬁc to gB-2 of HHV-2 virus was used as negative
control, MAb H17L2 speciﬁc to HA of PR8, kindly provided by
Dr. Gerhard (USA) was used as positive control. MAb 107L (Vareckova
et al., 1995) speciﬁc to NP of PR8 was used in rapid culture assay
(RCA). Irrelevant IMS raised against MHV68 was kindly provided by
Dr. Chalupkova from Department Microbiology and Virology of the
Faculty of Sciences, Comenius University, Bratislava.
Fig. 4. List of peptides used. Peptide sequences and their location within PB1-F2 molecule are indicated. Moreover application of individual peptides is indicated. All the
peptides were designed according to PR8 (H1N1) PB1-F2 amino acid sequence (ACN: ABD77684) except HA2170–178 peptide which was from the A/Mississippi/1/1985(H3N2)
derived (ACN: AAB69835). Gray rectangles represent synthetically added cystein residue to facilitate peptide conjugation to KLH. Vector NTI Advanced 11.5.0 software
package was used to sequence alignment.
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Passive Abs transfer: Groups of 8–16 mice were passively i.v.
immunized with puriﬁed MAbs: 100/100 mg AG55þLB66, 30 mg
H17L2 and 150 mg 499 per mouse. Groups of 16 mice were
passively immunized i.v. by PAbs: 160 mg IgG anti PB1-F2-MBP,
60 mg IgG anti PR8 and 150 mg IgG anti MBP. Mice were infected i.n.
1LD50 of PR8 2 h post receiving antibodies.
Peptide-KLH and pDNA immunization: Groups.of 16 mice were
i.p. immunized with two doses of 100 mg N3–13 or M42–53 or C71–83
KLH conjugates with complete or incomplete Freund's adjuvant
per mouse in two week intervals. Control groups were immunized
with puriﬁed virus or KLH (50 mg per mouse). Ten days post the
ﬁnal immunization, blood was collected and serum assayed for the
presence of immunogen-speciﬁc Abs. For DNA vaccination groups
of 14 mice were i.m. immunized with three doses of 50 mg of pPB1-
F2, pNter.PB1-F2, pCter.PB1-F2, pHA or pPB1-F2 Stop 3aa or PBS in
two week intervals. Ten days after last dose and serum was
assayed for presence of speciﬁc Abs. Stop3aa mutation construct
revealed by sequencing during PB1-F2 cloning was used as
negative control.
Infection: Mice were i.n. infected with 1 LD50 of PR8 virus
diluted in 40 ml PBS.
RT-PCR: To determine viral RNA, previously published assay
was employed (Kosik et al., 2012) and the NS gene was used as a
marker (Birch-Machin et al., 1997). Total RNA was extracted
from 100 ml of mouse lung homogenate using a Total RNA Isola-
tion Kit (SbsBio), reverse-transcribed using an oligo(T) primer
with Mu-MLV reverse transcriptase (Fermentas), and subjected to
PCR ampliﬁcation using the PR8 virus NS gene-speciﬁc primers
AC: CY035146 (5′-GCTGGAAAGCAGATAGTGGA-3′[forward] and
5′-GCCTGGTCCATTCTGATACA-3′[reverse]). β-actin was used as
internal control with the primers AC: NM_007393 (5′-AGGTGA-
CAGCATTGCTTCTG-3′[forward] and Betact Rev 5′-GCTGCCTCAA-
CACCTCAAC-3′[reverse]). The cycling consisted of 95 1C for 5 min,
94 1C for 15 s, 58 1C for 30 s, 35 cycles of 72 1C for 30 s, and 72 1C
for 5 min. PCR products were separated by agarose gel electro-
phoresis and stained with ethidium bromide.
ELISA: Peptides of PB1-F2, PB1-F2-MBP, MBP, synthetic full
length PB1-F2 and PR8 puriﬁed virus were adsorbed onto wells of
microtiter plates (Costar), washed, and saturated with 1% of
BSA. Initial 100-fold diluted serum samples were serially diluted
and added into the wells. Following incubation and washing,
the binding of immunoglobulins to antigens was detected with
rabbit anti-mouse IgG conjugated to horseradish peroxidase and
1,2-phenylene-diamine-dihydrochloride at 492 nm (Krejnusova
et al., 2009). Anti PB1-F2-MBP serum diluted 200-fold was
analyzed at the same conditions. The antibody titer was calculated
as the reciprocal of the sample dilution at the point where the
titration curve crossed the cutoff line. Cutoff value was determined as
2-fold absorbance measured for negative controls or NMS samples.
Rapid culture assay (RCA): Viral lung titer was measured as
described previously (Tkacova et al., 1997). Brieﬂy, 96-well cell
culture plates were seeded with 2.5105 MDCK cells per well
and incubated at 37 1C overnight. The cells were incubated
with aliquots of serial dilutions of mouse lung homogenates
(100 ml/well) for 45 min, washed, and exposed to growth medium
containing TPCK-trypsin (Sigma) (95 ml/well) for 18 h. The cells
were ﬁxed, washed and then treated with the NP-speciﬁc MAb
107L, followed by the polyclonal rabbit anti-mouse HRP conjugate,
both at 37 1C for 1 h. Finally, the cells were stained with ami-
noethyl carbazole(Sigma) in dimethylformamide for 30 min. The
virus titer was calculated as the reciprocal of the highest sample
dilution yielding at least one single stained cell.
Indirect immunoﬂuorescence: MDCK cells were grown on glass
cover slips to 60–70% conﬂuence. The cells were transfected with
plasmid DNA using Turbofect (Fermentas). The cells were ﬁxed
with 3% paraformaldehyde (Sigma) in PBS for 10 mins and
permeabilized with 1% Triton X-100 (KochLight) for 60 s. Samples
were washed three times with PBS and incubated with 250-fold
diluted IMS raised against PB1-F2-MBP for 1 h at room tempera-
ture. Subsequently, the washing step was repeated as described
previously, and the cells were incubated for 1 h with the 100-fold
diluted secondary goat anti mouse FITC conjugated antibody
(DAKO). For conﬁrmation of PB1-F2 variants (either full length
or N terminal or C terminal part) expression, samples were
incubated with AG55 MAb speciﬁc to N terminal part of the PB1-
F2 or 50-fold diluted IMS anti KLH-PB1-F2 73–87aa for 1 h at room
temperature. Samples were washed and incubated 1 h at room
temperature with 100-fold diluted goat anti mouse Texas Red
conjugated secondary antibody (Sigma Aldrich). After the ﬁnal
wash step, the samples were mounted with DAPI (4′,6-diamino-2-
phenylindole) containing mounting medium (Santa Cruz Bio-
technologies). Fluorescence was visualized with a confocal micro-
scope LSM Zeiss 510 Meta (Kosik et al., 2012).
Western blotting (WB): Six well tissue culture plates were
seeded with MDCK cells. At 60–70% conﬂuence cells were trans-
fected with 4 mg of the different pDNA. 24HPT and 48HPT cells
were washed twice with PBS and directly lysed on the plate by
2XSDS lysis buffer and incubated for 5 min at 100 1C. Samples
were centrifuged 15 min 14,000 RPM and separated by 15% SDS-
polyacrylamide gel electrophoresis (PAGE) under reducing condi-
tions. The proteins were electroblotted onto nitrocellulose mem-
brane (Schleicher and Schuell; 0.45 μm) in 10 mM Tris-glycine
buffer with 20% methanol. Blots were blocked overnight at 4 1C in
PBS containing 1% BSA, washed twice with PBS. Membrane was
cut and strips were incubated with ﬁve 1000-fold diluted MAb
AC-15 anti β-actin MAb (Sigma-Aldrich) or AG55 MAb (5 mg/ml) or
1000-fold diluted IMS anti PB1-F2-MBP in PBS containing 1% BSA
and 0,001% NP-40 for 2 h at RT and washed in PBS. After extensive
washing, the strips were incubated for 2 h with Alexa Fluor 790
Goat Anti-Mouse IgG (HþL) (Molecular Probess) diluted in 1%
BSA and 0,001% NP-40 in PBS and washed with 0.001% NP-40 in
PBS. Immunoreactive bands were visualized by Odyssey CLx
Infrared Imaging System (Li-Cor).
Statistical analysis: Statistical analysis was performed using
GraphPad Prism softwareV5.00 (GraphPad Software Inc., San
Diego, CA). Unpaired two-tailed Student t-test was applied to
comparison of experimental groups to negative control groups in
individual experiments. The differences were considered statisti-
cally signiﬁcant at po0,05.
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